The Trump Administration has proposed voluntary and mandatory MFN pricing models requiring pharmaceutical companies to align U.S. prices with international reference prices through rebates to CMS. However, significant exemptions are likely to shield most top 20 pharmaceutical companies with voluntary MFN agreements and drugs under IRA negotiation.
Curta’s Sean Sullivan and Jens Grueger along with Kristi Martin provide a description of the MFN policies and discuss implications to industry in a new policy paper.